公开(公告)号：EP1615613A2

公开(公告)日：2006-01-18

申请号：EP04750236.4

申请日：2004-04-16

申请人： Enanta Pharmaceuticals, Inc.

发明人： NAKAJIMA, Suanne ,  SUN, Ying ,  TANG, Datong ,  XU, Gouyou ,  PORTER, Brian ,  OR, Yat, Sun ,  WANG, Zhe ,  MIAO, Zhenwei

IPC分类号： A61K6/00

CPC分类号： C07K5/0804 ,  C07D487/04

摘要： The present invention relates to compounds of Formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：EP1615613B1

公开(公告)日：2009-11-04

申请号：EP04750236.4

申请日：2004-04-16

申请人： Enanta Pharmaceuticals, Inc.

发明人： NAKAJIMA, Suanne ,  SUN, Ying ,  TANG, Datong ,  XU, Gouyou ,  PORTER, Brian ,  OR, Yat, Sun ,  WANG, Zhe ,  MIAO, Zhenwei

IPC分类号： C07D487/04 ,  A61K31/38 ,  A61K31/395 ,  A61P31/12 ,  C07D401/12 ,  C07D409/14 ,  C07K5/08

CPC分类号： C07K5/0804 ,  C07D487/04

摘要： The present invention relates to compounds of Formula (I) or (II), or a pharmaceutically acceptable salt, ester, or prodrug, thereof: formula (I), formula (II): which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.